Yarrow Bioscience, Inc. 8-K

What Happened
VYNE Therapeutics Inc. announced the closing of its merger with Yarrow Bioscience, Inc. effective July 27, 2026. At the Effective Time all pre‑merger VYNE directors resigned and a six‑member board was appointed, with Rebecca Frey, Pharm.D. named Chief Executive Officer. Former VYNE executives David Domzalski (President & CEO), Iain Stuart, Ph.D. (CSO) and Mutya Harsch (CLO) resigned as officers and were terminated effective July 27, 2026; their separations are treated as without “cause” for change‑in‑control purposes and may be eligible for previously disclosed separation benefits upon execution of releases. The company adopted new indemnification agreements for directors and officers and a new Code of Business Conduct and Ethics on July 27, 2026. Financial disclosures and pro forma combined results as of March 31, 2026 are incorporated by reference from the proxy/prospectus.

Key Details

• Effective date: July 27, 2026 (Closing/Effective Time).
• New senior officers appointed: Rebecca Frey (CEO), Tyler Zeronda (CFO), Steven Ryder, M.D. (CMO), Lori Payton, Ph.D. (Chief Development Officer), Rachael Alford, Ph.D. (COO).
• New Board (6 members): Rebecca Frey, Mona Ashiya, Steven Hoerter, Bill Lundberg, Peter Silverman and William White; Bill Lundberg named Chair.
• Equity plans approved and ratified: Yarrow 2026 Stock Incentive Plan (initial pool 2,688,931 shares, annual automatic increases = 5% of diluted stock each Jan 1 from 2027–2036) and 2026 ESPP (initial pool 336,116 shares, annual increases up to 1% diluted stock or 2,500,000 shares through 2036).
• Executive pay highlights: CEO Frey base $660,000, target bonus 55%; COO Alford base $470,000, target bonus 40%. Specified severance and change‑in‑control (CIC) protections are set in their amended offer letters (e.g., Frey: 12 months pay outside CIC window; 1.5x pay+18 months benefits if termination during CIC Protection Period).
• Governance/legal items: new indemnification agreements for directors/officers (Exhibit 10.4) and new Code of Conduct effective July 27, 2026 (Exhibit 14.1). Press release and investor presentation furnished (Exhibits 99.1, 99.2).

Why It Matters

• Governance and leadership: The merger caused a complete board and management refresh, with a new CEO and C‑suite that will set strategy and execution going forward—important for investors watching pipeline advancement and corporate direction.
• Compensation and obligations: The company has established stock‑based incentive and employee purchase plans with defined share pools and automatic annual increases, which create frameworks for employee and director equity awards and may affect future share counts. The filing also documents severance and CIC protections for certain executives and new indemnification commitments for directors and officers.
• Financial disclosure: Audited and unaudited Pre‑Merger Yarrow financials and pro forma combined financial information through March 31, 2026 are incorporated by reference, providing the basis for assessing the combined company's recent performance.

Keywords: merger, Yarrow, VYNE, CEO appointment, CFO, stock incentive plan, ESPP, indemnification, pro forma financials.